Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: Effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation

Journal of Clinical Endocrinology and Metabolism

Volumn 88, Issue 9, 2003, Pages 4110-4115

  Barbaro, Daniele ^a   Boni, Giuseppe ^d   Meucci, Giuseppe ^b   Simi, Umberto ^c   Lapi, Paola ^a   Orsini, Paola ^a   Pasquini, Cristina ^a   Piazza, Francesca ^a   Caciagli, Marco ^b   Mariani, Giuliano ^d  

^a Spedali Riuniti   (Italy)

^b Azienda Sanitaria Locale 6   (Italy)

^c Spedali Riuniti   (Italy)

^d Istituto di Medicina Nucleare   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE; RADIOACTIVE IODINE; RECOMBINANT THYROTROPIN; THYROXINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HISTOPATHOLOGY; HORMONAL REGULATION; HUMAN; HUMAN TISSUE; HYPOTHYROIDISM; INJECTION; LOW DRUG DOSE; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; STANDARDIZATION; STATISTICAL SIGNIFICANCE; SURGICAL TECHNIQUE; THYROID CARCINOMA; THYROXINE BLOOD LEVEL; TREATMENT OUTCOME;

ADULT; AGED; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IODINE; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; THYROGLOBULIN; THYROID NEOPLASMS; THYROTROPIN; THYROXINE; TREATMENT OUTCOME; WHOLE-BODY COUNTING;

EID: 0141787986     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2003-030298     Document Type: Article

References (26)

1. Mazzaferri EL, Jhiang SM 1994 Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97:418-428
2. De Groot LJ, Kaplan EL, McMormick M, Strauss F 1990 Natural history, treatment and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 71:414-424
3. Hay ID, McConahey WM, Goellner JR 2002 Managing patients with papillary thyroid carcinoma: insights gained from the Mayo Clinic's experience of treating 2,512 consecutive patients during 1940 through 2000. Trans Am Clin Climatol Assoc 113:241-260
4. Larsen PR, Davies TF, Hay ID 1998 The thyroid gland. In: Wilson JD, Foster DW, Kronenberg HM, Larsen PR, eds. Williams textbook of endocrinology. 9th Ed. Philadelphia: WB Saunders Company; 389-515
5. Wartofsky L, Sherman SI, Gopal J, Schlumberger M, Hay ID 1998 Therapeutic controversy. The use of radioactive iodine in patients with papillary and follicular thyroid cancer. J Clin Endocrinol Metab 83:4195-4203
6. Sclumberger M 1998 Papillary and follicular thyroid carcinoma. N Engl J Med 338:297-306
7. Wartofsky L 2002 Management of low-risk well differentiated thyroid cancer based only on thyroglobulin measurement after recombinant human thyrotropin. Thyroid 12:583-590
8. Szkudlinski MW, Thotakura NR, Bucci I, Joshi LR, Tsai A, East-Palmer J, Shiloach J, Weintraub BD 1993 Purification and characterization of recombinant human thyrotropin (TSH) isoforms produced by Chinese hamster ovary cells: the role of sialylation and sulfation in TSH bioactivity. Endocrinology 133:1490-1503
9. Pellegriti G, Scollo C, Giuffrida D, Vigneri R, Squatrito S, Pezzino V 2001 Usefulness of recombinant human thyrotropin in the radiometabolic treatment of selected patients with thyroid cancer. Thyroid 11:1025-1030
10. Chiu AC, Delpassand ES, Sherman SI 1997 Prognosis and treatment of brain metastases in thyroid carcinoma. J Clin Endocrinol Metab 82:3637-3642
11. Mariani G, Ferdeghini M, Augeri C, Villa G, Taddei GZ, Scopinaro G, Boni G, Bodei L, Rabitti C, Molinari E, Bianchi R 2000 Clinical experience with recombinant human thyrotrophin (rhTSH) in the management of patients with differentiated thyroid cancer. Cancer Biother Radiopharm 15:211-217
12. Adler ML, Macapinlac HA, Robbins RJ 1998 Radioiodine treatment of thyroid cancer with the aid of recombinant human thyrotropin. Endocr Pract 4:282-286
13. Robbins RJ, Voelker E, Wang W, Macapinlac HA, Larson SM 2000 Cornpassionate use of recombinant human thyrotropin to facilitate radioiodine therapy:case report and review of literature. Endocr Pract 6:460-464
14. Robbins RJ, Tuttle RM, Sonenberg M, Shaha A, Sharaf R, Robbins H, Fleisher M, Larson SM 2001 Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin. Thyroid 11:865-869
15. Berg G, Lindstedt G, Suurkula M, Jansson S 2002 Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone. J Endocrinol Invest 25:44-52
16. Pacini F, Molinaro E, Castagna MG, Lippi F, Ceccarelli C, Agate L, Elisei R, Pinchera A 2002 Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab 87:4059-4062
17. Nagata K, Takasu N, Akamine H, Ohshiro C, Komiya I, Murakami K, Suzawa A, Nomura T 1998 Urinary iodine and thyroid antibodies in Okinawa, Yamagata, Hyogo, and Nagano, Japan: the differences in iodine intake do not affect thyroid antibody positivity. Endocr J 45:797-803
18. Mazzaferri EL 1996 Radioiodine and other treatments and outcomes. In: Werner and Ingbar's the thyroid: a fundamental and clinical text. Philadelphia, New York: Lippincott-Raven; 922-945
19. Cavalieri RR 1996 Nuclear imaging in the management of thyroid carcinoma. Thyroid 6:485-492
20. Mazzaferri EL, Kloos RT 2002 Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? J Clin Endocrinol Metab 87:1490-1498
21. Pacini F, Capezzone M, Elisei R, Ceccarelli C, Taddei D, Pinchera A 2002 Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J Clin Endocrinol Metab 87:1499-1501
22. Odink J, Bogaards JJ, Sandman H, Egger RJ, Arkesteyn GA, De Jong P 1988 Excretion of iodide in 24-h urine as determined by ion-pair reversed-phase liquid chromatography with electrochemical detection. J Chromatogr 431:309-316
23. Toft A, Beckett G 2002 Use of recombinant thyrotropin. Lancet 359:1874-1875
24. Robbins RJ, Larson SM, Sinha N, Shaha A, Divgi C, Pentlow KS, Ghossein R, Tuttle RM 2002 A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation. J Nucl Med 43:1482-1488
25. Maxon HR, Thomas SR, Boehringer A, Drilling J, Sperling MI, Sparks JC, Chen IW 1994 A low iodine diet in 131I ablation of thyroid remnants. Clin Nucl Med 8:123-126
26. Nijhuis TF, Van Weperen W, De Klerk JMH 1999 Costs associated with the withdrawal of thyroid hormone suppression therapy during the follow-up treatment of well-differentiated thyroid cancer. Tijdschr Nucl Geneeskd 21:98-100